Company Overview of Muscular Dystrophy Association, Inc.
NONCOMMERCIAL RESEARCH ORGANIZATIONS, NSK
3300 East Sunrise Drive
Tucson, AZ 85718
Founded in 1950
Key Executives for Muscular Dystrophy Association, Inc.
Compensation as of Fiscal Year 2015.
Muscular Dystrophy Association, Inc. Key Developments
Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004
Feb 5 16
Catabasis Pharmaceuticals, Inc. and the Muscular Dystrophy Association (MDA) announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment of patients with Duchenne muscular dystrophy (DMD). Under the collaboration, MDA will provide funding for transportation to participants who need to travel to take part in the study. Part A of the MoveDMD trial has completed and Catabasis recently reported positive top-line results for safety, tolerability and pharmacokinetics. Part B of the trial is expected to initiate in the first half of 2016. The boys in Part A of the trial will be asked to participate in Part B and additional participants will also be enrolled. Catabasis is currently identifying additional patients who are interested in participating in Part B of the trial. Enrollment criteria for Part B are expected to be similar to those for Part A. The incidence of DMD in the U.S. population is estimated to be between one in every 3,500 to one in 6,000 male births. The loss of a key muscle protein called dystrophin causes muscle wasting and weakness, eventually leading to the loss of ambulation, difficulty breathing, and heart failure. Life expectancy is currently the mid- to late 20s. CAT-1004 is an oral small-molecule that Catabasis believes has the potential to be a disease-modifying therapy for the treatment of Duchenne, regardless of the underlying dystrophin mutation. CAT-1004 is an inhibitor of NF-kB, a protein that is chronically activated in DMD as well as multiple other skeletal muscle disorders. In animal models of DMD, CAT-1004 inhibited NF-kB, reduced muscle degeneration and increased muscle regeneration.
Muscular Dystrophy Association Appoints Grace Pavlath as Vice President
Sep 25 14
Muscular Dystrophy Association announced that Dr. Grace Pavlath, an accomplished muscle disease researcher and tenured professor in the Department of Pharmacology at the Emory University School of Medicine, has been named as Vice President Scientific Program Director. Beginning October 31, 2014, Dr. Pavlath will become a key member of the company’s Mission Leadership Team and will be responsible for overall management and further development of the company’s scientific program focused on delivering effective therapies for more than 40 neuromuscular diseases and ALS.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries